- Home
- PYPD vs BNR Comparison
PYPD vs BNR Comparison
Compare PYPD & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYPD
- BNR
- Stock Information
- Founded
- PYPD 2008
- BNR 2014
- Country
- PYPD Israel
- BNR China
- Employees
- PYPD N/A
- BNR N/A
- Industry
- PYPD Medical/Dental Instruments
- BNR Medical Specialities
- Sector
- PYPD Health Care
- BNR Health Care
- Exchange
- PYPD Nasdaq
- BNR Nasdaq
- Market Cap
- PYPD 24.2M
- BNR 28.6M
- IPO Year
- PYPD 2020
- BNR 2020
- Fundamental
- Price
- PYPD $3.56
- BNR $3.77
- Analyst Decision
- PYPD Strong Buy
- BNR
- Analyst Count
- PYPD 2
- BNR 0
- Target Price
- PYPD $12.00
- BNR N/A
- AVG Volume (30 Days)
- PYPD 8.1K
- BNR 21.0K
- Earning Date
- PYPD 11-13-2024
- BNR 11-29-2024
- Dividend Yield
- PYPD N/A
- BNR N/A
- EPS Growth
- PYPD N/A
- BNR N/A
- EPS
- PYPD N/A
- BNR N/A
- Revenue
- PYPD N/A
- BNR $70,154,674.00
- Revenue This Year
- PYPD N/A
- BNR $52.90
- Revenue Next Year
- PYPD N/A
- BNR $48.35
- P/E Ratio
- PYPD N/A
- BNR N/A
- Revenue Growth
- PYPD N/A
- BNR N/A
- 52 Week Low
- PYPD $2.95
- BNR $2.62
- 52 Week High
- PYPD $9.20
- BNR $9.99
- Technical
- Relative Strength Index (RSI)
- PYPD 54.93
- BNR 61.38
- Support Level
- PYPD $3.30
- BNR $2.65
- Resistance Level
- PYPD $3.59
- BNR $3.89
- Average True Range (ATR)
- PYPD 0.21
- BNR 0.30
- MACD
- PYPD 0.02
- BNR 0.12
- Stochastic Oscillator
- PYPD 68.27
- BNR 90.32
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.